Search results
Showing 3351 to 3400 of 4091 results for patient
NICE has a key role in UK licensing and the evaluation of and access to new and innovative products for the health system.
Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]
Discontinued Reference number: GID-TA10164
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]
Discontinued Reference number: GID-TA10596
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]
In development Reference number: GID-TA11228 Expected publication date: TBC
Discontinued Reference number: GID-TA10566
Faricimab for treating wet age-related macular degeneration (TA800)
Evidence-based recommendations on faricimab (Vabysmo) for wet age-related macular degeneration in adults.
Evidence-based recommendations on high-intensity focused ultrasound for glaucoma in adults. This involves using high-intensity ultrasound to destroy a small amount of the tissue that makes fluid in the eye.
View recommendations for HTG527Show all sections
Advises NICE on the formulation of its guidance on the safety and efficacy of interventional procedures.
Advises NICE on the formulation of its guidance on the safety and efficacy of interventional procedures.
Reviewing 2025: Producing faster rigorous guidance to make an impact on patients' lives We look back on the guidance we've produced in...
In development Reference number: GID-TA11104 Expected publication date: TBC
This guideline covers methods for monitoring the wellbeing of the baby during labour. It includes risk assessment to determine the appropriate level of fetal monitoring, using clinical assessment in addition to fetal monitoring, and interpreting and acting on monitoring findings.
Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]
Discontinued Reference number: GID-TA10377
Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]
Discontinued Reference number: GID-TA10711
Discontinued Reference number: GID-TA11289
Suspected neurological conditions: recognition and referral (NG127)
This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.
Show all sections
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]
Discontinued Reference number: GID-TAG393
Discontinued Reference number: GID-TA10277
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]
In development Reference number: GID-TA10900 Expected publication date: TBC
Evidence-based recommendations on faricimab (Vabysmo) for diabetic macular oedema in adults.
Biotin for treating primary and secondary progressive multiple sclerosis [ID919]
Discontinued Reference number: GID-TA10099
NICE recommends new treatment option for highly active multiple sclerosis
Thousands of people living with a form of multiple sclerosis (MS) will benefit from greater treatment choice, following new guidance from NICE.
headache disorders II or this guideline. Outcomes should include change in patient‑reported headache days, responder rate and incidence...
Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]
Discontinued Reference number: GID-TA10363
Discontinued Reference number: GID-TA10109
Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.
NICE Advice - a fee-based advisory service for pharmaceutical and healthtech companies seeking to enter the NHS market,
Cellulitis and erysipelas: antimicrobial prescribing (NG141)
This guideline sets out an antimicrobial prescribing strategy for adults, young people, children and babies aged 72 hours and over with cellulitis and erysipelas. It aims to optimise antibiotic use and reduce antibiotic resistance.
Evidence-based recommendations on interferon alfa (Pegasys or ViraferonPeg) and ribavirin for people with chronic hepatitis C.
In development Reference number: GID-TA10568 Expected publication date: TBC
Discontinued Reference number: GID-TA10271
This guideline covers diagnosing and managing myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS) in children, young people and adults. It aims to improve awareness and understanding about ME/CFS and when to suspect it, so that people are diagnosed earlier. It includes recommendations on diagnosis, assessment and care planning, safeguarding, access to care and managing ME/CFS and its symptoms.
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]
In development Reference number: GID-TA10899 Expected publication date: TBC
This guide gives an overview of the process for developing evidence summaries. Evidence summaries provide advice but do not include recommendations and are not formal NICE guidance
Data on the cancer recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.
Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]
Discontinued Reference number: GID-TA10597
also needed to understand the long-term impact of duration on costs and patient outcomes, by comparing 6-week reablement services with...
This guideline covers diagnosing and treating fertility problems. It aims to reduce variation in practice and improve the way fertility problems are investigated and managed.
Any explanatory notes(if applicable) Why this is important:- In patients with submucosal (T1b) N0 oesophageal adenocarcinoma (OAC), the...
Discontinued Reference number: GID-TA10234
the research into the optimum treatment for varicose veins has involved patients with varicose veins in CEAP stages C2 and C3, so little...
Discontinued Reference number: GID-TA10739
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]
Discontinued Reference number: GID-TA10764
Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]
Discontinued Reference number: GID-HST10038
Erythrocyte encapsulated asparaginase for treating acute lymphoblastic leukaemia [ID864]
Discontinued Reference number: GID-TA10047
bone mineral density (BMD). Input of BMD into the questionnaire in such patients will therefore generate the same fracture risk whether...
there is little empirical evidence to guide healthcare professionals or patients in choosing which disorder should be treated first....
Learning disabilities and behaviour that challenges: service design and delivery (NG93)
This guideline covers services for children, young people and adults with a learning disability (or autism and a learning disability) and behaviour that challenges. It aims to promote a lifelong approach to supporting people and their families and carers, focusing on prevention and early intervention and minimising inpatient admissions.
or more years. Neither FRAX nor QFracture has been examined in treated patients, and it is not known whether the ability of clinical...
Hepatitis B and C testing: people at risk of infection (PH43)
This guideline covers raising awareness of and testing for hepatitis B and C infection. It aims to ensure that people at increased risk of hepatitis B and C infection are tested.